Dermata Therapeutics (NASDAQ:DRMA – Get Rating) and Selecta Biosciences (NASDAQ:SELB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Dermata Therapeutics and Selecta Biosciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Dermata Therapeutics and Selecta Biosciences' revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dermata Therapeutics and Selecta Biosciences, as provided by MarketBeat.com.

Dermata Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 249.65%. Selecta Biosciences has a consensus target price of $5.33, indicating a potential upside of 210.08%. Given Dermata Therapeutics' higher possible upside, equities research analysts plainly believe Dermata Therapeutics is more favorable than Selecta Biosciences.

Institutional and Insider Ownership

1.6% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of Selecta Biosciences shares are owned by institutional investors. 36.3% of Dermata Therapeutics shares are owned by insiders. Comparatively, 30.5% of Selecta Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Dermata Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

Selecta Biosciences beats Dermata Therapeutics on 7 of the 10 factors compared between the two stocks.

About Dermata Therapeutics

(Get Rating)

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

About Selecta Biosciences

(Get Rating)

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.